TY - JOUR T1 - Late Breaking Abstract - Monocyte-derived macrophages display an inflammatory memory several months post SARS-CoV-2 infection JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.OA4117 VL - 58 IS - suppl 65 SP - OA4117 AU - Sina Bohnacker AU - Franziska Hartung AU - Fiona Henkel AU - Alessandro Quaranta AU - Johan Kolmert AU - Alina Priller AU - Paul Lingor AU - Adam Chaker AU - Percy Knolle AU - Carsten Schmidt-Weber AU - Craig Wheelock AU - Julia Esser-von Bieren Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/OA4117.abstract N2 - Monocytes and macrophages drive the inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and they are a major source of eicosanoids in airway inflammation. Here we report that monocyte-derived macrophages (MDM) from SARS-CoV-2-infected individuals with mild disease show an inflammatory transcriptional and metabolic imprint several (3-5) months after SARS-CoV-2 infection. MDM from convalescent SARS-CoV-2-infected individuals showed higher expression of fatty acid-metabolic enzymes and increased production of pro-inflammatory eicosanoids, particularly 5-lipoxygenase-derived leukotrienes, which correlated with symptoms and SARS-CoV-2 specific antibody titers. Following stimulation with spike protein or LPS, post COVID-19 MDM exhibited an exaggerated induction of inflammatory chemokines (particularly CCL2) as well as T-cell suppressive enzymes and receptors. Corticosteroids reduced inflammatory cytokine-, but increased leukotriene production in post COVID-19 macrophages. Thus, SARS-CoV-2 infection leaves an inflammatory imprint in the monocyte/macrophage compartment that drives aberrant effector functions and eicosanoid metabolism, possibly explaining long-term sequelae in patients recovering from mild COVID-19.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA4117.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -